Xilio Therapeutics is a biopharmaceutical company focused on developing highly-potent, targeted immuno-oncology therapeutics. The company’s proprietary Aklusion™ platform technology allows biologics to be specifically activated in the tumor microenvironment, and with precisely tailored properties, expanding the universe of natural immune-activating proteins that can be safely delivered. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for patients living with cancer. To learn more, please visit www.xiliotx.com.
The company is financed by blue chip investors F-Prime Capital Partners and Atlas Venture. Xilio has licensed key technology from Thomas Jefferson University and City of Hope. The company is located in Cambridge, Massachusetts.
- Rene Russo Chief Executive Officer
- Joseph Farmer Chief Operating Officer
- Tim Clackson President & EVP R&D
- Ronan O'Hagan SVP Research & Translational Sciences